SCHEMBL6908200

SCHEMBL6908200

CCCCOC=Cc1ccc(F)c([C@H]2C[C@H]2NC(=O)Nc2ccc(Cl)cn2)c1OCOC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR1 P21462 2/20 0.40
FPR2 P25090 2/20 0.40
L3MBTL1 Q9Y468 4/20 0.36
MAPK1 P28482 3/20 0.36
NPC1 O15118 2/20 0.36
GLA P06280 1/20 0.36
ALDH1A1 P00352 5/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
RAB9A P51151 3/20 0.35
LMNA P02545 3/20 0.35
NFKB1 P19838 1/20 0.35
CASP3 P42574 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7559875 0.83 FPR1 (0.40) FPR1FPR2L3MBTL1MAPK1NPC1
SCHEMBL6908592 0.81 FPR1 (0.45) FPR1FPR2L3MBTL1NPC1ALDH1A1
SCHEMBL6906043 0.80 FPR1 (0.46) FPR1FPR2L3MBTL1MAPK1NPC1
SCHEMBL6905018 0.72 SMN1; SMN2 (0.48) FPR1FPR2L3MBTL1MAPK1NPC1
SCHEMBL6905976 0.72 SMN1; SMN2 (0.48) FPR1FPR2L3MBTL1MAPK1NPC1
SCHEMBL6906796 0.72 SMN1; SMN2 (0.48) FPR1FPR2L3MBTL1MAPK1NPC1
SCHEMBL6903793 0.72 SMN1; SMN2 (0.48) FPR1FPR2L3MBTL1MAPK1NPC1
SCHEMBL6906802 0.72 SMN1; SMN2 (0.48) FPR1FPR2L3MBTL1MAPK1NPC1
SCHEMBL6906200 0.72 SMN1; SMN2 (0.56) FPR1FPR2L3MBTL1NPC1ALDH1A1
SCHEMBL27514889 0.71 FPR1 (0.45) FPR1FPR2L3MBTL1MAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040116418-A1 Compounds and methods for inhibition of HIV and related viruses MEDIVIR AB (SE) 2004-06-17 US disclosed
US-20020132794-A1 Compounds and methods for inhibition of HIV and related viruses MEDIVIR AB 2002-09-19 US disclosed
US-6376492-B1 GUANIDINE DERIVATIVES MEDIVIR AB (SE) 2002-04-23 US disclosed
US-5849769-A N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection MEDIVIR AB (SE) 1998-12-15 US disclosed
EP-0706514-B1 COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES MEDIVIR AB (SE) 1998-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132794-A1 Compounds and methods for inhibition of HIV and related viruses POLRMT, POLM, POLR1E FPR1 3393/4885FPR2 4096/4885L3MBTL1 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.